



**Samaritan
Pharmaceuticals, Inc.**
101 Convention
Center Drive, Suite 310
Las Vegas, NV 89109
Tel: 702.735.7001
Fax: 702.737.7016

Samaritan Staff

Dr. Janet Greeson
C.E.O. and President

Eugene Boyle
C.F.O. and C.O.O.

Dr. Tom Lang
Chief Drug Development Officer

George Weaver
Regulatory Affairs

Kristi Eads
V.P. of Business Development

Dr. Christos Dakas
Managing Director, S.E.

Dianne Thompson
Comptroller

Richard Brown
Investor Relations

Barrie Fuller
Operations and
Investor Relations

Terri Hess
Office Manager

Monica Jones
Administrative Assistant

Rosemary Fuller
Executive Assistant

Marcie Still
Secretary

Mike Smith
Information Technology

Thomas Vosicky
Creative and Web Design

Sharon Gerrie
Corporate Publicist

In this issue:

- In-Licensing New Products in 2007
- New Website for the New Year
- Samaritan's Pipeline is Growing Too!

VOLUME III • ISSUE I

www.SamaritanPharma.com

JAN. - FEB, 2007.

Samaritan Starts New Year with New Products

Samaritan Pharmaceuticals is starting off the new year by in-licensing eight drugs from three different manufacturers located in the United States and abroad.

In-licensing means Samaritan has purchased defined sales and marketing rights to a drug owned by another company.

Samaritan's in-licensing plan will market and sell the eight new drugs in various Eastern European countries under the supervision of Samaritan Pharmaceuticals Europe (SPE).

Christos Dakas, Ph.D. and managing director of SPE, along with Eugene Boyle, Samaritan's CFO/COO, will implement the plan.

From the Italian pharmaceutical company, **Molteni Farmaceutici**, Samaritan has in-licensed the following drugs: Oramorph®, Morphine Sulfate, Methadone, Naloxone Molteni®, Naltrexone®, and Mepivamol®.

Oramorph® and morphine sulfate are narcotic analgesics used for pain control. Methadone, Naloxone Molteni®, and Naltrexone® have various uses in drug addiction therapy. Mepivamol® is a local anesthetic of intermediate duration and low systemic toxicity.

From **Three Rivers Pharmaceuticals**, Pennsylvania, Samaritan has in-licensed the anti-fungal drug, Amphocil®, (called Amphotec® in the U.S.).

From **ONY, Inc.**, New York, Infasurf®, an intratracheal suspension drug treating Respiratory Distress Syndrome (RSD) has been in-licensed.

Samaritan has exclusive rights to sell Infasurf® in the following countries: Turkey, Serbia, Bosnia, Albania, Macedonia, Egypt and Syria. Dr. Janet Greeson, Samaritan CEO, commented on the in-licensing, saying, "In-licensing will play an



important role in Samaritan's inaugural endeavor of achieving revenue from the sale of drugs, which will also impact the profitability of the Company."

See "Products" on Pages 2 & 3

Samaritan Website gets New Look

For those who visit the Samaritan Pharmaceuticals Website, from time to time, get ready for something completely different to flash on your screen.

Tom Vosicky, Samaritan's new designer, is giving its Website an overhaul. Look for new graphics, tables, links and updated information on what's happening with Samaritan. The homepage will feature the latest news about Samaritan, so check it often as Samaritan is always moving forward.

The new Website will also include expanded information on all of Samaritan's drugs and products. It is our goal to make individual drug product information the most complete and extensive available anywhere on the Internet.

Officially, the new Website went online on Jan. 02, 2007. Samaritan invites all of its Website visitors to take an extra minute or two to click through the whole site now that the makeover is complete. Then, we'd love to hear your comments.

Samaritan team members, from scientists to support staff, strive to make everything we present to the public the very best there is to offer. We hope you enjoy our new Website.

For a sample picture of the new www.samaritanpharma.com, go to page 4. Enjoy!

Samaritan's New In-Licensed Drugs

Name: ORAMORPH®

Type: Narcotic analgesic
Maker: Molteni Farmaceutici
Actions: Oramorph® is an oral solution of morphine sulfate used to manage moderate to severe chronic pain. Oramorph® is a *Schedule II* substance in the United States, making it illegal to use or possess without a prescription. Abuse of this drug could lead to physical and/or psychological dependence.



www.amphotec.net
www.infasurf.net



Name: INFASURF®

Type: Exogenous Surfactant
Maker: ONY, Inc.
Action: INFASURF® treats and prevents Respiratory Distress Syndrome (RDS). RDS occurs when infants lack surfactant, a natural substance normally produced in the body, which is necessary for lungs to function normally. INFASURF® is used exclusively in hospitals with a neonatal intensive care unit (NICU).



Name: AMPHOCIL®


Type: Anti-fungal
Maker: Three Rivers Pharmaceuticals
Action: The European brand name Amphocil® is an injectable used to treat invasive aspergillosis, a life threatening systemic fungal infection attacking, primarily, patients with a compromised immune system.
 Amphocil® is also used to treat opportunistic infections such as Candida, Mucor, and Cryptococcus.
 Amphocil® is a prescription medication primarily used in hospitals. In the United States, Amphocil® is labeled as Amphotec®.



www.SamaritanPharma.com/Marketed_Products.asp

Samaritan's New In-Licensed Drugs

Name: METHADONE HCL



Type: Narcotic agonist
Maker: Molteni Farmaceutici
Action: Methadone Hydrochloride is an opiate agonist delivered as a syrup in strengths of 1 and 5 mg/ml .

Methadone prevents heroin or morphine from interacting with receptors for natural painkillers called endorphins, blocking the effects of the addictive drugs and reducing the physical cravings.

Methadone HCL is a *Schedule II* substance in the United States, making it illegal to use or possess without a prescription.

Name: NALTREXONE HCL

Type: Narcotic antagonist
Maker: Molteni Farmaceutici
Action: The brand name Naltrexone HCL® is delivered in a 50 mg tablet form. The drug is used by patients to help stay drug-free after an initial detoxification process. Naltrexone HCL® decreases cravings for alcohol and narcotics.



Name: NALOXONE MOLTENI®

Type: Narcotic antagonist
Maker: Molteni Farmaceutici
Action: The brand name Naloxone Molteni® (naloxone hydrochloride) is an injectable delivered in 0,04 and 0,4 mg, 1 and 2 ml ampoules. A narcotic antagonist, used to treat an overdose of narcotics by reversing the effect of opioids.



Name: MORPHINE SULFATE


Type: Narcotic analgesic
Maker: Molteni Farmaceutici
Action: Morphine sulfate is an injectable opioid. The drug is used in the treatment of chronic, acute pain. Morphine sulfate is a *Schedule II* substance in the United States, making it illegal to use or possess without a prescription.



Name: MEPIVAMOL®

Type: General Anesthetic
Maker: Molteni Farmaceutici
Action: The brand name Mepivamol®, for mepivacaine, is an effective and reliable local anesthetic of intermediate duration and low systemic toxicity. It is widely used for regional anesthetic procedures such as IVRA, infiltration, epidural blockade, plexus and peripheral nerve blockade.





Samaritan Website Gets a New Look...
www.SamaritanPharma.com

Officially, the Website went live Jan. 2, 2007.



It is our goal to make individual drug product information the most complete and extensive available anywhere on the Internet.

The Samaritan Pharmaceuticals, Inc. Newsletter is published monthly from 101 Convention Center Dr., Ste. 310, Las Vegas, NV 89109. Ph.702-735-7001.
 Editor/Writer: Sharon Gerrie, Art/Design: Tom Vosicky
 Please direct all comments and story ideas for the Samaritan newsletter to:
sgerrie@samaritanpharma.com